LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes

Atherosclerosis

Volumn 192, Issue 1, 2007, Pages 138-147

  Murdoch, Susan J ^a   Boright, Andrew P ^b   Paterson, Andrew D ^b   Zinman, Bernard ^b   Steffes, Michael ^c   Cleary, Patricia ^d   Edwards, Karen ^a   Marcovina, Santica S ^a   Purnell, Jonathan Q ^e   Brunzell, John D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF MINNESOTA   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e Center for the Study of Weight Regulation and Associated Disorders   (United States)

Author keywords

Apo E genotype; E2 2; LDL; LDL composition; VLDL remnants

Indexed keywords

APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; FEMALE; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 34247103197     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.04.023     Document Type: Article

References (36)

1. Mahley R.W., Huang Y., and Rall Jr. S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 40 (1999) 1933-1949
2. Utermann G., Langenbeck U., Beisiegel U., and Weber W. Genetics of the apolipoprotein E system in man. Am J Hum Genet 32 (1980) 339-347
3. Rall Jr. S.C., Weisgraber K.H., and Mahley R.W. Isolation and characterization of apolipoprotein E. Methods Enzymol 128 (1986) 273-287
4. Utermann G. Apolipoprotein E mutants, hyperlipidemia and arteriosclerosis. Adv Exp Med Biol 183 (1985) 173-188
5. Rall Jr. S.C., Newhouse Y.M., Clarke H.R., et al. Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. J Clin Invest 83 (1989) 1095-1101
6. Davignon J., Gregg R.E., and Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8 (1988) 1-21
7. Woollett L.A., Osono Y., Herz J., and Dietschy J.M. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc Natl Acad Sci USA 92 (1995) 12500-12504
8. Demant T., Bedford D., Packard C.J., and Shepherd J. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest 88 (1991) 1490-1501
9. Chait A., Brunzell J.D., Albers J.J., and Hazzard W.R. Type-III hyperlipoproteinaemia ("remnant removal disease"). Insight into the pathogenetic mechanism. Lancet 1 (1977) 1176-1178
10. Chait A., Hazzard W.R., Albers J.J., Kushwaha R.P., and Brunzell J.D. Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia. Metabolism 27 (1978) 1055-1066
11. Havel R.J., Kotite L., Vigne J.L., et al. Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency. J Clin Invest 66 (1980) 1351-1362
12. Sing C.F., and Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37 (1985) 268-285
13. Ehnholm C., Lukka M., Kuusi T., Nikkila E., and Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res 27 (1986) 227-235
14. Boerwinkle E., and Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet 42 (1988) 104-112
15. Eichner J.E., Kuller L.H., Ferrell R.E., Meilahn E.N., and Kamboh M.I. Phenotypic effects of apolipoprotein structural variation on lipid profiles. III. Contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the healthy women study. Arteriosclerosis 10 (1990) 379-385
16. Hallman D.M., Boerwinkle E., Saha N., et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 49 (1991) 338-349
17. Xhignesse M., Lussier-Cacan S., Sing C.F., Kessling A.M., and Davignon J. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb 11 (1991) 1100-1110
18. Schaefer E.J., Lamon-Fava S., Johnson S., et al. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler Thromb 14 (1994) 1105-1113
19. Winocour P.H., Tetlow L., Durrington P.N., Ishola M., Hillier V., and Anderson D.C. Apolipoprotein E polymorphism and lipoproteins in insulin-treated diabetes mellitus. Atherosclerosis 75 (1989) 167-173
20. Eichner J.E., Ferrell R.E., Kamboh M.I., et al. The impact of the apolipoprotein E polymorphism on the lipoprotein profile in insulin-dependent diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study IX. Metabolism 41 (1992) 347-351
21. Blaauwwiekel E.E., Beusekamp B.J., Sluiter W.J., Hoogenberg K., and Dullaart R.P. Apolipoprotein E genotype is a determinant of low-density lipoprotein cholesterol and of its response to a low-cholesterol diet in Type 1 diabetic patients with elevated urinary albumin excretion. Diabet Med 15 (1998) 1031-1035
22. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 35 (1986) 530-545
23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
24. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22 (1999) 99-111
25. Warnick G.R. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol 129 (1986) 101-123
26. Marcovina S.M., Albers J.J., Wijsman E., Zhang Z., Chapman N.H., and Kennedy H. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 37 (1996) 2569-2585
27. Marcovina S.M., Albers J.J., Gabel B., Koschinsky M.L., and Gaur V.P. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 41 (1995) 246-255
28. Hokanson J.E., Austin M.A., and Brunzell J.D. Measurement and clinical significance of low-density lipoprotein subclasses. In: Rifai N., Warnick G.R., and Dominiczak M.H. (Eds). Handbook of Lipoprotein Testing (1997), American Association of Clinical Chemistry Press, Washington 267-282
29. Hixson J.E., and Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31 (1990) 545-548
30. McFarlane C., Young I.S., Hare L., Mahon G., and McEneny J. A rapid methodology for the isolation of intermediate-density lipoprotein: characterization of lipid composition and apoprotein content. Clin Chim Acta 353 (2005) 117-125
31. Eisenberg S. Plasma lipoprotein conversions: the origins of low-density and high-density lipoproteins. Ann N Y Acad Sci 348 (1980) 30-47
32. Purnell J.Q., Hokanson J.E., Marcovina S.M., Steffes M.W., Cleary P.A., and Brunzell J.D. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. Jama 280 (1998) 140-146
33. Murdoch S.J., and Breckenridge W.C. Effect of lipid transfer proteins on lipoprotein lipase induced transformation of VLDL and HDL. Biochim Biophys Acta 1303 (1996) 222-232
34. Salo M.K., Rantanen R., Huupponen T., Lehtimaki T., and Jokela H. Apolipoprotein E phenotypes and plasma lipids in diabetic children and adolescents. Eur J Pediatr 152 (1993) 564-568
35. Purnell J.Q., Marcovina S.M., Hokanson J.E., et al. Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44 (1995) 1218-1226
36. Carr M.C., and Brunzell J.D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89 (2004) 2601-2607